Evidence map›Paper›PMID 16193083›Full record

SynthesisLeukemia2005

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).

M Aoudjhane, M Labopin, N C Gorin, A Shimoni, T Ruutu, H-J Kolb, F Frassoni, J M Boiron, J L Yin, J Finke and 11 more

Registry-linked trialAbstract readComparative StudyMeta-AnalysisMulticenter Study
PubMed Publisher
In one paragraph

Synthesis in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05674539 (Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome), which is not on this map. Cited by 186 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 5 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05674539 phase3enrolling by invitationnot on this mapstarted 2023, after this paper: background citation

Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Multi-Center, Phase III Study

TypeinterventionalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2023 to 2025Enrolled200ConditionsAcute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell TransplantationArmsFludarabine and Busulfan, Fludarabine and Melphalan
3 · Its place in the literature

Who cites it

186 citing papers in PubMed, 5 syntheses or guidelines pooled it, 453 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

126 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

M AoudjhaneEA1638 Université Paris 6, Acute Leukemia Working Party and European Group of Blood and Marrow Transplant Office Paris, Paris, France.
M Labopin
N C Gorin
A Shimoni
T Ruutu
H-J Kolb
F Frassoni
J M Boiron
J L Yin
J Finke
H Shouten
D Blaise
M Falda
A A Fauser
J Esteve
E Polge
S Slavin
D Niederwieser
A Nagler
V Rocha
Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
European Society for Blood and Marrow Transplantation · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II-IV) and transplant-related mortality were significantly decreased (P=0.01 and P<10(-4), respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.

Indexed as

AgedCause of DeathDose-Response Relationship, DrugDose-Response Relationship, RadiationFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMultivariate AnalysisRecurrenceRegistriesRetrospective Studies

Identifiers

PMID16193083
OpenAlexW2084267226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.